AbInitio Bio develops AI foundation models for biologic drug manufacturability and process optimization.
AbInitio Bio has raised $500K in total funding. The most recent round was Pre-Seed. The last funding was announced in May 2026.
AbInitio Bio's investors include Y Combinator.
AbInitio Bio is headquartered in San Francisco, United States.
AbInitio Bio develops AI foundation models for biologic drug manufacturability and process optimization.
AbInitio Bio is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AbInitio Bio — Funding & Investors." VCBacked, May 22, 2026, https://www.vcbacked.co/company/abinitio-bio. Accessed August 14, 2026.
VCBacked. (2026). AbInitio Bio — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/abinitio-bio
{{cite web |title=AbInitio Bio — Funding & Investors |url=https://www.vcbacked.co/company/abinitio-bio |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated